The abstract is read at the publisher; the summary is JClub's.
circ_0042819 is highly expressed in bone marrow and plasma from multiple myeloma patients, and its overexpression is strongly linked to disease progression and unfavorable prognosis.
- Why it matters: Drug resistance limits outcomes in multiple myeloma, and ferroptosis induction is a therapeutic opportunity; this work targets a circRNA axis that may regulate ferroptosis and treatment sensitivity.
- What they did: The study shows circ_0042819 binds UPF1 in MM cells to increase PLA2G6 mRNA expression by stabilizing it, while the circ_0042819–PLA2G6 axis suppresses ferroptosis via phospholipid remodeling.
- The result: Depleting circ_0042819 or PLA2G6 increases sensitivity to proteasome inhibitors bortezomib and carfilzomib by promoting ferroptosis in vitro and in vivo, supporting circ_0042819 as a diagnostic/prognostic biomarker and therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.